public-private partnership
Johnson & Johnson announces change in senior leadership role
Tom Cavanaugh has been appointed as Executive Vice President, Worldwide Chairman Innovative Medicine
AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo
Rinvoq is the first and only systemic medication approved in the EU for NSV
Pfizer announces phase 3 results for nonsegmental vitiligo treatment
Litfulo delivered significant, clinically meaningful improvements for both face and body
Johnson & Johnson commits $5.5bn to end remaining talc litigation
The resolution comes after plaintiffs were unable to prove that J&J’s talc products caused their ovarian cancer
Pfizer’s Talzenna plus Xtandi gets FDA Priority Review for metastatic prostate cancer
The phase 3 trial showed greater than 50% improvement in radiographic progression-free survival
Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies
Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis
Sanofi announces phase 3 study data for infantile-onset Pompe disease
Pompe disease is a rare, progressive neuromuscular disease, with infantile onset being the most aggressive form
Pfizer announces phase 3 results for potential non-small cell lung cancer treatment
Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and progression-free survival
Sanofi’s Cenrifki approved in Europe for secondary progressive MS without relapses
SPMS is a debilitating stage of MS where patients experience increasing levels of disability
AbbVie to acquire Apogee Therapeutics in $10.9bn deal
The acquisition includes clinical-stage candidates for atopic dermatitis and asthma
Sanofi appoints Paulo Fontoura as Global Head of R&D
Fontoura previously held senior leadership roles at Xaira Therapeutics and Roche
Sanofi’s Sarclisa approved by MHRA as UK’s first anti-cancer treatment given via on-body injector
It is the first anticancer treatment in the UK and globally to be administered this way and a first in multiple myeloma